Gene Therapy for AMN Clinical Trial Update

SwanBio Therapeutics have announced additional preclinical data that supports Clinical Advancement of First AAV-Based Gene Therapy for Adrenomyeloneuropathy. SBT101 preclinical studies demonstrate improvement in behavioral and biochemical markers of disease. Further support for dosing strategy for Phase 1/2 study initiating later in 2022.

To read press release: SwanBio Press Release